Abstract
The number of biological products is increasing. Both new biopharmaceutics for new indications as well as variants of existing molecules will be marketed soon. In addition, patents of a number of the first generation biopharmaceutics will expire in the coming years, potentially opening the market for "biogenerics". For treating many diseases, such as chronic hepatitis C virus, chronic hepatitis B virus and multiple sclerosis, a number of alternative biological products could be available, which at face value may seem to be similar to the long established original product. Physicians confronted with many different alternatives have to be able to choose the best product for their patients to start treatment, and if and how to change to another product if a patient does not respond. In this article the authors consider the comparability of biopharmaceutical products.
| Original language | English |
|---|---|
| Pages (from-to) | 300-301 |
| Number of pages | 2 |
| Journal | Pharmaceutical Journal |
| Volume | 268 |
| Issue number | 7187 |
| Publication status | Published - 2 Mar 2002 |
